Skip to main content
Caplight Logo









Lipo-Immuno Tech

Lipo-Immuno Tech

Private
Mount Pleasant, South CarolinaHealthcare & Life Scienceshttps://www.theredpoppyrichmond.com/

Last Round

Accelerator

Apr 10, 2025

Total Funding Raised

$3.02M

Company Overview

Lipo-Immuno Tech is a biotechnology company that develops anti-cancer strategies utilizing lipid metabolism/signaling and immunotherapy, with potential applications for neurodegenerative disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2G

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

preclinical biotechcancer immunotherapyoncology therapeuticsadoptive cell therapytumor-infiltrating lymphocytesTILscell therapyacute myeloid leukemiaAMLlipid metabolismsmall molecule therapeuticsdrug discoverymitophagy inductionpyridinium-ceramide compoundsneurodegenerative disease researchuniversity spin-outSTTR grant

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lipo-Immuno Tech Comparables

Compare Lipo-Immuno Tech with similar companies based on industry and business-model similarity.

Lipo-Immuno Tech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MPC Therapeutics AG
74%
TATUM Bioscience
68%
Bexion Pharmaceuticals
68%

Lipo-Immuno Tech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorApr 10, 2025
GrantJul 23, 2024
GrantSep 15, 2023
GrantApr 4, 2023
GrantFeb 15, 2020

Lipo-Immuno Tech Investors

Notable investors and investment history

Lipo-Immuno Tech investors
InvestorRounds
National Cancer InstituteGrant
NIH RADxGrant
SCbioDriveAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 10, 2025

    Raised an Accelerator round with SCbioDrive as an investor.

  • Jul 23, 2024

    $1M grant awarded by NIH RADx

Lipo-Immuno Tech Filings

Explore SEC and related filing metadata, where available.

Lipo-Immuno Tech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Lipo-Immuno Tech's valuation, stock price, and market status.

Is Lipo-Immuno Tech a public or private company?

Lipo-Immuno Tech is a private company.

What is the current stock price of Lipo-Immuno Tech?

Lipo-Immuno Tech is a private company with no public stock price. No recent secondary market data is available.

How much is Lipo-Immuno Tech worth (valuation)?

Valuation information for Lipo-Immuno Tech is not publicly available.

Can I buy Lipo-Immuno Tech stock?

Lipo-Immuno Tech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Lipo-Immuno Tech's last funding round?

Lipo-Immuno Tech's most recent funding round was Accelerator on April 10, 2025.

Who are the main investors in Lipo-Immuno Tech?

Key investors in Lipo-Immuno Tech include National Cancer Institute, NIH RADx.

Will Lipo-Immuno Tech IPO soon?

No public IPO plans have been announced for Lipo-Immuno Tech.

How can I track Lipo-Immuno Tech secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Lipo-Immuno Tech's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMount Pleasant, South Carolina
Year Founded2018
Last FundingApr 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?